1753
Health-economic analysis in idegasp co-formulation (Ryzodeg®) comparing with other insulin treatment regimens in patients with type 2 diabetes mellitus
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Kolbin A.S., Kurylev A.A., Balykina Yu.E., Proskurin M.A., Globin M.V., Litvinova A.A. Health-economic analysis in idegasp co-formulation (Ryzodeg®) comparing with other insulin treatment regimens in patients with type 2 diabetes mellitus // Pharmacoeconomics: theory and practice. - 2020. - Т.8, №4. - С. 17-27 DOI: https://doi.org/10.30809/phe.4.2020.3
Comments0